ASAM Releases Detox Guidance for Medetomidine Withdrawal

The nation’s leading addiction medicine society has published new clinical guidance on an emerging threat in the drug supply.

The American Society of Addiction Medicine released a Clinical Consideration on medetomidine intoxication and withdrawal, giving treatment teams their clearest direction yet on a syndrome that is reshaping medical detox for people who use unregulated opioids.

A Veterinary Sedative Is Changing the US Opioid Supply

Medetomidine is a veterinary sedative that acts as an imidazoline and alpha-2 adrenergic receptor agonist. It has recently emerged as an adulterant in the unregulated opioid supply, and ASAM describes it as associated with a uniquely severe withdrawal syndrome that is forcing rapid adjustments in clinical practice.

The guidance arrives at a complicated moment. Although overdose mortality in the United States has recently declined, ASAM notes that morbidity tied to unregulated substance use continues to exact a serious toll.

The opioid supply has been shifting quickly, with combinations of potent synthetic opioids, sedatives, analgesics, and synthetic precursors creating new medical complexities for patients with substance use disorders.

Intoxication and Withdrawal Are Two Distinct Syndromes

The document draws a line that matters enormously at the bedside. Acute medetomidine toxicity looks like persistent sedation accompanied by bradycardia, a slowed heart rate, and occasionally hypotension.

Withdrawal looks like the opposite: autonomic hyperactivity that develops hours after someone stops using, with the body swinging into overdrive rather than shutting down.

Confusing the two can lead clinicians in the wrong direction, which is why the Clinical Consideration organizes itself around two key questions. First, for patients presenting with medetomidine intoxication, what medical interventions effectively manage it?

Second, for patients with moderate to severe medetomidine withdrawal, what medical interventions effectively manage that? The document also covers treatment in outpatient and residential settings, guidance for specific populations, and example protocols in use as of November 2026.

What the Guidance Means for Medical Detox

Standard opioid withdrawal protocols were built for opioids alone. A patient whose supply was adulterated with medetomidine may show withdrawal that does not respond the way clinicians expect, because a second drug’s withdrawal syndrome is running alongside the first.

That reality raises the stakes for medically supervised detox, where monitoring can catch autonomic hyperactivity early and treatment can be adjusted in real time.

The guidance was last updated on November 10, 2026, and was developed by a committee that included Bridget R. Durkin, Michael J. Lynch, and Jeanmarie Perrone, with review by ASAM’s Quality Improvement Council and field reviewers across addiction medicine and emergency care. ASAM will hold a live webinar on the guidance on Tuesday, December 1, 2026, from 3 to 4 p.m. Eastern Time.

Why Unsupervised Withdrawal Is Riskier Than Ever

The emergence of medetomidine strengthens a message Detox.com has long carried: withdrawal from today’s unregulated drug supply is not a safe do-it-yourself project.

A person may believe they are withdrawing from fentanyl alone while a veterinary sedative drives a second, severe syndrome on top of it. Medical supervision turns a dangerous guessing game into a monitored clinical process.

The same principle applies across substances. Alcohol and benzodiazepine withdrawal can be life-threatening without medical care, and opioid withdrawal complicated by adulterants now demands clinical oversight as well. Detox programs with medical monitoring are built for exactly this complexity.

Finding Medically Supervised Detox

Anyone who uses unregulated opioids, or who loves someone who does, should treat the ASAM guidance as a prompt to plan ahead. Medical detox centers provide monitored withdrawal management and can coordinate the transition into medication-assisted treatment with buprenorphine, methadone, or naltrexone once withdrawal is stabilized.

Asking a program how it handles complex or polysubstance withdrawal is a fair question, and this month it is an especially timely one. You can find local detox centers by searching Detox.com’s directory. Call 800-996-6135Sponsored to get connected to treatment today.